<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04269733</url>
  </required_header>
  <id_info>
    <org_study_id>2020-015</org_study_id>
    <nct_id>NCT04269733</nct_id>
  </id_info>
  <brief_title>Risk of Pacing-induced Cardiomyopathy</brief_title>
  <official_title>Pacing-induced Cardiomyopathy - the Importance of Right Ventricular Pacing Site and Patterns of Dyssynchronous Myocardial Activation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aalborg University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Svend Andersens Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peacs</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aalborg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karl G Andersens Fond</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sygekassernes Helsefond</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aalborg University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the association between right ventricular pacing and the risk of&#xD;
      pacing-induced cardiomyopathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      Right ventricular (RV) pacing may lead to pacing-induced cardiomyopathy (PICM) and heart&#xD;
      failure (HF). The detrimental effects of RV pacing have been attributed to the abnormal and&#xD;
      dyssynchronous electrical and mechanical activation of the myocardium. The activation is&#xD;
      affected by the RV pacing site. Understanding the consequences of different RV pacing sites&#xD;
      and the patterns of dyssynchrony may help to choose the optimal treatment for the individual&#xD;
      patient.&#xD;
&#xD;
      Aim and objectives:&#xD;
&#xD;
      The overall aim of this project is to investigate the association between RV pacing site and&#xD;
      the risk of PICM. Contrast enhanced cardiac computed tomography (CT) will be applied for&#xD;
      precise localization of the RV pacing. Furthermore, investigation of the association between&#xD;
      PICM and different mechanical and electrical myocardial activation patterns during RV pacing&#xD;
      will be conducted using new echocardiographic and electrocardiographic methods.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      The study is designed as a retrospective cohort study with clinical follow-up. Patients with&#xD;
      prior pacemaker implantation due to advanced atrioventricular block will be included. The&#xD;
      study baseline is retrospective and defined as time of pacemaker implantation and follow-up&#xD;
      is time of inclusion. Baseline data will be extracted from the Danish Pacemaker- and ICD&#xD;
      Registry, electronic medical records (EMR) and review of echocardiographs. Follow-up data&#xD;
      will be extracted from existing data in the EMRs as well as generated during a follow-up&#xD;
      visit with a clinical examination. For assessment of cardiac function, RV lead position and&#xD;
      electrical and mechanical activations patterns, the examination will include a transthoracic&#xD;
      echocardiography, an electrocardiogram, a 3-dimensional chest photo, and a contrast-enhanced&#xD;
      cardiac CT. Data will be analysed for differences between those who develop PICM and those&#xD;
      who do not.&#xD;
&#xD;
      Expected outcomes and perspectives:&#xD;
&#xD;
      The hope is that this project will generate knowledge and awareness on pacemaker treatment&#xD;
      and the risk of PICM. Understanding the pathophysiology behind PICM is key to learning how to&#xD;
      prevent it. Accordingly, this project has the potential to contribute to improving pacemaker&#xD;
      treatment and the quality of care for the large and still growing PM population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Actual">August 1, 2021</completion_date>
  <primary_completion_date type="Actual">August 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pacing-induced cardiomyopathy</measure>
    <time_frame>After ≥ 1 years of exposure to right ventricular pacing</time_frame>
    <description>Time to development of PICM. PICM is defined as ≥ 10% decrease in LVEF resulting in LVEF &lt; 50% after pacemaker implantation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite endpoint of new-onset heart failure</measure>
    <time_frame>After ≥ 1 year of exposure to right ventricular pacing</time_frame>
    <description>HF diagnosis and/or HF hospitalization and/or Upgrading from a DDD PM to a CRT system after pacemaker implantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LVEF</measure>
    <time_frame>After ≥ 1 year of exposure to right ventricular pacing</time_frame>
    <description>Change in LVEF after pacemaker implantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New-onset atrial fibrillation and/or atrial flutter</measure>
    <time_frame>After ≥ 1 years of exposure to right ventricular pacing</time_frame>
    <description>New diagnosis of atrial fibrillation and/or atrial flutter after pacemaker implantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LV end-diastolic volume</measure>
    <time_frame>After ≥ 1 years of exposure to right ventricular pacing</time_frame>
    <description>Change in LV end-diastolic volume after pacemaker implantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LV end-systolic volume</measure>
    <time_frame>After ≥ 1 years of exposure to right ventricular pacing</time_frame>
    <description>Change in LV end-systolic volume after pacemaker implantation.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">153</enrollment>
  <condition>Pacemaker DDD</condition>
  <condition>Atrioventricular Block</condition>
  <condition>Pacing-Induced Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Subjects with a DDD-pacemaker due to high-degree AV block</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Right ventricular pacing</intervention_name>
    <description>Right ventricular pacing from a DDD pacemaker implanted due to high-degree AV block</description>
    <arm_group_label>Subjects with a DDD-pacemaker due to high-degree AV block</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with a normal or near-normal ejection fraction prior to pacemaker implantation who&#xD;
        received a DDD-pacemaker due to high-degree AV block ≥ 1 years prior to screening.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female ≥ 18 years&#xD;
&#xD;
          -  De novo DDD PM implanted at Aalborg University Hospital&#xD;
&#xD;
          -  PM implantation due to advanced AV block&#xD;
&#xD;
          -  Duration of pacemaker treatment ≥ 1 year at time of screening&#xD;
&#xD;
          -  Normal LVEF (≥50%) prior to PM implantation&#xD;
&#xD;
          -  Actively attending follow-up at the PM outpatient clinic at Aalborg University&#xD;
             Hospital after PM implantation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No written informed consent&#xD;
&#xD;
          -  Baseline TTE not available or insufficient quality for assessment of LVEF&#xD;
&#xD;
          -  Contraindications to a new contrast CT if no previous contrast-enhanced cardiac CT,&#xD;
             showing RV lead position, is available&#xD;
&#xD;
          -  RV pacing load &lt; 40%.&#xD;
&#xD;
          -  Deceased&#xD;
&#xD;
          -  Not attending follow-up at the PM outpatient clinic at Aalborg University Hospital&#xD;
             after PM implantation&#xD;
&#xD;
          -  Device complications with removal of original implanted pacing lead &gt; 3 months after&#xD;
             primary implantation&#xD;
&#xD;
          -  Subjects with severe ischemic heart disease and severe valvular heart disease.&#xD;
&#xD;
          -  Terminal illness or unable to provide informed consent at time of screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Cardiology, Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 12, 2020</study_first_submitted>
  <study_first_submitted_qc>February 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aalborg University Hospital</investigator_affiliation>
    <investigator_full_name>Patricia Fruelund</investigator_full_name>
    <investigator_title>MD, clinical assistant, PhD student</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Atrioventricular Block</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

